Y. Takamatsu

Inter-individual variability of human hepatic glutathione S-transferase isozymes assessed by inhibitory capacity.

Y Takamatsu, T Inaba, T. Inaba, 1994, Toxicology.

Phase I Clinical Study of MCI-186 (Edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one) in Healthy Volunteers

M. Murasaki, Masahiko Tanaka, Y. Takamatsu, 1998 .

O-24 Independent regulation of intrarenal angiotensin receptors expression during the development of cyclosporine A-induced hypertension(KIDNEYS AND URINARY EXCRETION SYSTEM)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)

Y. Iwase, N. Tsutsui, P. Silber, 2004 .

Research and development of the free radical scavenger edaravone as a neuroprotectant

Toshiaki Watanabe, Masahiko Tanaka, Y. Takamatsu, 2004 .

Metabolism of 2- and 3-tert-butyl-4-hydroxyanisole (2- and 3-BHA) in the rat. (II): Metabolism in forestomach and covalent binding to tissue macromolecules.

A. Yoshitake, M. Hirose, J. Miyamoto, 1987, Toxicology.

Substrate specificity for formation of cholesterol ester conjugates from fenvalerate analogues and for granuloma formation.

A. Yoshitake, J. Miyamoto, Y. Takamatsu, 1988, Xenobiotica; the fate of foreign compounds in biological systems.

Stereoselective formation of a cholesterol ester conjugate from fenvalerate by mouse microsomal carboxyesterase(s).

J. Miyamoto, Y. Takamatsu, H. Kaneko, 1986, Journal of biochemical toxicology.

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.

Y. Shimada, S. Matsumoto, K. Muro, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[Research and development of the free radical scavenger edaravone as a neuroprotectant].

Toshiaki Watanabe, Masahiko Tanaka, Y. Takamatsu, 2004, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.